WO2009074331A3 - Test diagnostique precoce et differentiel de la maladies d'alzheimer - Google Patents

Test diagnostique precoce et differentiel de la maladies d'alzheimer Download PDF

Info

Publication number
WO2009074331A3
WO2009074331A3 PCT/EP2008/010552 EP2008010552W WO2009074331A3 WO 2009074331 A3 WO2009074331 A3 WO 2009074331A3 EP 2008010552 W EP2008010552 W EP 2008010552W WO 2009074331 A3 WO2009074331 A3 WO 2009074331A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
early
marker
differential diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/010552
Other languages
English (en)
Other versions
WO2009074331A2 (fr
Inventor
Edna Gruenblatt
Peter Riederer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of WO2009074331A2 publication Critical patent/WO2009074331A2/fr
Publication of WO2009074331A3 publication Critical patent/WO2009074331A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un gène marqueur ou d'un produit génique de celui-ci ou d'une combinaison de gènes marqueurs ou de produits géniques de ceux-ci, ce(s) gène(s) marqueur(s) étant sélectionné(s) dans le groupe constitué par SLC1A7, SLC1A2, TF, GRIK4, CNR2, IGF-1R, CHAK2, GRINL1A, CHRNA1, GSTM1, FTH1, NDUFS3, LYST, SYNII, COG2, PEX5, STX5A, HIST1H3E, IRS4, RPL36A, GFAP, IDE et DEFA1. Ce(s) gène(s) sert/servent de marqueur(s) périphérique(s) dans le diagnostic d'une maladie neurodégénérative.
PCT/EP2008/010552 2007-12-11 2008-12-11 Test diagnostique precoce et differentiel de la maladies d'alzheimer Ceased WO2009074331A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07024011 2007-12-11
EP07024011.4 2007-12-11

Publications (2)

Publication Number Publication Date
WO2009074331A2 WO2009074331A2 (fr) 2009-06-18
WO2009074331A3 true WO2009074331A3 (fr) 2009-08-20

Family

ID=40459843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/010552 Ceased WO2009074331A2 (fr) 2007-12-11 2008-12-11 Test diagnostique precoce et differentiel de la maladies d'alzheimer

Country Status (1)

Country Link
WO (1) WO2009074331A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3358354B1 (fr) 2008-01-18 2020-07-15 President and Fellows of Harvard College Procédés de détection de signatures de maladies ou d'états dans des fluides corporels
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
CA2806293A1 (fr) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Procedes de detection de maladies/pathologies auto-immunes ou liees au systeme immunitaire
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
WO2014164362A1 (fr) 2013-03-09 2014-10-09 Harry Stylli Procédés de détection du cancer de la prostate
EP4202441A3 (fr) 2013-03-09 2023-07-26 Immunis.AI, Inc. Profil d'expression génétique dans les macrophages pour le diagnostic du cancer
CN103713120B (zh) * 2013-12-20 2015-09-23 浙江大学 基于液相芯片技术判断体液环境中细胞状态的方法
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
DK3171174T3 (en) 2015-11-20 2018-01-22 Geroa Diagnostics S L Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014547A2 (fr) * 2000-08-15 2002-02-21 Yeda Research And Development Co. Ltd. Methode destinee au diagnostic et au suivi de la schizophrenie et d'autres troubles mentaux et neurodegeneratifs
WO2005020784A2 (fr) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Signatures d'expression genique de cellules de substitution permettant d'evaluer l'etat physique d'un patient
WO2006003414A2 (fr) * 2004-07-02 2006-01-12 King's College London Biomarqueurs de la maladie d'alzheimer
WO2006134390A2 (fr) * 2005-06-17 2006-12-21 Randox Laboratories Ltd Methode destinee a diagnostiquer une maladie neurodegenerative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014547A2 (fr) * 2000-08-15 2002-02-21 Yeda Research And Development Co. Ltd. Methode destinee au diagnostic et au suivi de la schizophrenie et d'autres troubles mentaux et neurodegeneratifs
WO2005020784A2 (fr) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Signatures d'expression genique de cellules de substitution permettant d'evaluer l'etat physique d'un patient
WO2006003414A2 (fr) * 2004-07-02 2006-01-12 King's College London Biomarqueurs de la maladie d'alzheimer
WO2006134390A2 (fr) * 2005-06-17 2006-12-21 Randox Laboratories Ltd Methode destinee a diagnostiquer une maladie neurodegenerative

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BLENNOW K ET AL: "CSF markers for pathogenic processes in Alzheimer's disease: Diagnostic implications and use in clinical neurochemistry", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 61, no. 3, 15 August 2003 (2003-08-15), pages 235 - 242, XP002347178, ISSN: 0361-9230 *
CARRETTE O ET AL: "A PANEL OF CEREBROSPINAL FLUID POTENTIAL BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE", PROTEOMICS, WILEY - VCH VERLAG, WEINHEIM, DE, vol. 3, no. 8, 1 August 2003 (2003-08-01), pages 1486 - 1494, XP008022060, ISSN: 1615-9853 *
GALASKO D: "BIOLOGICAL MARKERS AND THE TREATMENT OF ALZHEIMER'S DISEASE", JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 17, no. 2, 1 October 2001 (2001-10-01), pages 119 - 125, XP008044457, ISSN: 0895-8696 *
HOLLANDER E ET AL: "Antemortem markers of Alzheimer's disease", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 7, no. 5, 1 September 1986 (1986-09-01), pages 367 - 387, XP024367058, ISSN: 0197-4580, [retrieved on 19860901] *
MAES ET AL: "Transcriptional profiling of Alzheimer blood mononuclear cells by microarray", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 28, no. 12, 12 October 2007 (2007-10-12), pages 1795 - 1809, XP022295299, ISSN: 0197-4580 *
MULDER C ET AL: "GENETIC AND BIOCHEMICAL MARKERS FOR ALZHEIMER'S DISEASE: RECENT DEVELOPMENTS", ANNALS OF CLINICAL BIOCHEMISTRY, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 37, no. 5, 1 January 2000 (2000-01-01), pages 593 - 607, XP009007381, ISSN: 0004-5632 *
PASINETTI G M: "USE OF CDNA MICROARRAY IN THE SEARCH FOR MOLECULAR MARKERS INVOLVED IN THE ONSET OF ALZHEIMER'S DISEASE DEMENTIA", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 65, no. 6, 15 September 2001 (2001-09-15), pages 471 - 476, XP009006221, ISSN: 0360-4012 *
PUCHADES MAJA ET AL: "Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 118, no. 1-2, 21 October 2003 (2003-10-21), pages 140 - 146, XP002346222, ISSN: 0169-328X *
RETZ W ET AL: "Potential genetic markers of sporadic Alzheimer's dementia", PSYCHIATRIC GENETICS, RAPID COMMUNICATIONS OF OXFORD LTD, XX, vol. 11, no. 3, 1 September 2001 (2001-09-01), pages 115 - 122, XP009096877, ISSN: 0955-8829 *
SEUBERT P ET AL: "USE OF CSF-BASED MARKERS IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE", PHARMACOLOGICAL TREATMENT OF ALZHEIMER'S DISEASE: MOLECULAR ANDNEUROBIOLOGICAL FOUNDATIONS, XX, XX, 1 January 1997 (1997-01-01), pages 345 - 366, XP008013750 *
THIENHAUS O J ET AL: "BIOLOGIC MARKERS IN ALZHEIMER'S DISEASE", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 33, no. 10, 1 January 1985 (1985-01-01), pages 715 - 726, XP008055569, ISSN: 0002-8614 *
WEST JAMES D ET AL: "Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal.", CHEMICAL RESEARCH IN TOXICOLOGY NOV 2005, vol. 18, no. 11, November 2005 (2005-11-01), pages 1642 - 1653, XP002532249, ISSN: 0893-228X *

Also Published As

Publication number Publication date
WO2009074331A2 (fr) 2009-06-18

Similar Documents

Publication Publication Date Title
MY148558A (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2005067391A3 (fr) Test de diagnostic de la maladie de parkinson
WO2009059318A3 (fr) Gènes et polymorphismes associés à l'amd
WO2012143481A3 (fr) Marqueurs du cancer de la prostate
WO2009132656A3 (fr) Mise au point de ligands spécifiques de la sortiline
WO2008152656A3 (fr) Variants génétiques sur chr 15q24 servant de marqueurs et destinés à être utilisés dans le diagnostic, le pronostic et le traitement du syndrome d'exfoliation et du glaucome
WO2007140843A3 (fr) Essai relatif au diagnostic de la maladie d'alzheimer basé sur la détermination du rapport de produits de clivage abêta de la gamma-sécrétase
WO2005020784A3 (fr) Signatures d'expression genique de cellules de substitution permettant d'evaluer l'etat physique d'un patient
WO2006045318A3 (fr) Diagnostic et traitement des maladies immunitaires
WO2007056435A3 (fr) Maladies mediees par la dynamine et procedes et produits associes
WO2010033951A3 (fr) Procédé d'identification et de prédiction de la sclérose en plaques et de la réponse à la thérapie
WO2009087689A3 (fr) Nouvelles amorces pour l'identification d'un astrocytome, de ses grades et le pronostic d'un glioblastome
WO2007059064A3 (fr) Methodes associees au fgf2 pour diagnostiquer et traiter une depression
WO2005106041A3 (fr) Trousses et reactifs utilises pour diagnostiquer et pronostiquer des troubles genomiques
WO2012041292A3 (fr) Composés pour le diagnostic de maladies neurodégénératives sur la rétine
DE60037126D1 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
WO2007101094A3 (fr) Méthodes diagnostiques liées au bbs10 et réactifs pour syndrome de bardet-biedl
WO2010032154A3 (fr) Procédé pour le diagnostic de la dilatation du proventricule, et nécessaire à cet effet
WO2006003520A3 (fr) Gene de predisposition a l'autisme humain codant pour un facteur de transcription et ses utilisations
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
WO2010011626A3 (fr) Modulateurs pyridinylique de υ-sécrétase
WO2006087634A3 (fr) Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
WO2006003523A8 (fr) Gene humain de predisposition a l'autisme codant prkcb1 et procedes d'utilisation
WO2006090288A3 (fr) Genes humains de predisposition a l'autisme codant pour un transporteur de neurotransmetteur et utilisations associees
WO2013192522A3 (fr) Biomarqueurs de la démence à dégénérescence neurofibrillaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859210

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859210

Country of ref document: EP

Kind code of ref document: A2